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B-Type Natriuretic Peptide Forms in the General Population
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Richard J. Rodeheffer, MD, FACC,* Margaret M. Redfield, MD, FACC*
Rochester, Minnesota; and Singapore
Objectives This study was designed to determine whether alternate pro-B-type natriuretic peptide (proBNP) and BNP forms
circulate in the general population.
Background Bioactive BNP1-32 and NT-proBNP1-76 are derived from a precursor molecule, proBNP1-108. Recent data suggest
that aminodipeptidase-processed forms of BNP1-32 (BNP3-32) and of proBNP1-108 itself (proBNP3-108) may circu-
late and have additional diagnostic potential.
Methods Residents (age 45 years) of Olmsted County, Minnesota, underwent medical review, echocardiography,
and phlebotomy for 2 novel assays specific for proBNP3-108 and BNP3-32 and 2 commercial assays (Triage
BNP and Roche NT-proBNP). Groups included normal subjects (n  613), cardiovascular disease with nor-
mal ventricular function (n  1,043), preclinical ventricular dysfunction (ALVD, n  130), and chronic heart
failure (HF, n  52).
Results ProBNP3-108 levels were above assay detection limits in 68% of normal subjects (50th; 25th to 75th percen-
tiles: 7.85; 3.00 to 22.45 pmol/l) and correlated with age, gender, body size, and renal function and with
results of commercial assays. ProBNP3-108 levels were higher in ALVD (17.88; 6.07 to 42.76 pmol/l) or HF
(42.75; 20.51 to 65.73 pmol/l), where they correlated more strongly with commercial assays. BNP3-32 was
above assay detection limits in 22% of normal subjects; levels were not correlated with age, body size, or
renal function but were higher in HF. Neither novel assay was superior to commercial assays for the detec-
tion of ALVD or HF.
Conclusions The presence of alternate circulating proBNP and BNP forms provides evidence for diverse proBNP and BNP pro-
cessing in the general population. The physiologic consequences of these observations, both in terms of assay
performance and endogenous BNP bioactivity, deserve further study. (J Am Coll Cardiol 2007;49:1193–202)
© 2007 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.12.024w
p
t
b
p
(
p
d
N
(
a
a
c
e
s
weasurement of plasma levels of B-type natriuretic peptide
BNP) aids in the diagnosis of heart failure (HF) (1).
owever, levels of BNP measured using commercially
vailable assays have shown marked variation even in ho-
ogenous populations (1,2). This variability has remained
nexplained, as has the seemingly paradoxical sensitive and
ose-related vasodilator response to exogenous intravenous
dministration of BNP in HF patients whose endogenous
NP levels as measured by commercial BNP assays are
lready extremely high (1–3).
rom the *Division of Cardiovascular Diseases, Mayo Clinic and Foundation,
ochester, Minnesota; and †Yong Loo Lin School of Medicine, National University
f Singapore, Singapore. This study was funded by grants from the Public Health
ervice (NIH HL55502 and P01 HL 76611), Biosite, and Roche. Dr. Redfield
eceives research funding from Guidant, Medtronic, St. Jude Medical, Encysive,
lteon, and Cardiac Dimensions. A. Mark Richards, MD, PhD, served as Guest
ditor for this article.m
Manuscript received July 10, 2006; revised manuscript received October 31, 2006,
ccepted November 2, 2006.B-type natriuretic peptide is produced in cardiomyocytes,
here it is derived from the 108 amino acid (aa) precursor
roBNP. ProBNP is believed to be cleaved by the endopro-
ease corin upon secretion resulting in the formation of the
ioactive 32 aa BNP peptide (referred to as BNP1-32 or as
roBNP77-108) and the inert 76 aa N-terminal peptide
NT)-proBNP (proBNP1-76) (Fig. 1). This simple proBNP
rocessing scheme suggests only 2 circulating proBNP-
erived peptides, which commercially available BNP or
T-proBNP assays are assumed to specifically detect
Fig. 2, Table 1). Challenging this concept, a recent study of
dvanced HF patients with high BNP levels, as indicated by
commercial assay, demonstrated an absence of endogenous
irculating BNP1-32 when a highly accurate mass spectrom-
try technique was used (4). This led the authors to
peculate that alternate forms of proBNP-derived products
ere responsible for the high levels detected by the com-
ercial assay. Although this study did not identify what
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others have suggested that in-
tact proBNP1-108 may be one
such form (5– 8) and that com-
mercial BNP and NT-proBNP
assays potentially cross-react
with proBNP1-108 (9). Further,
BNP1-32 has been shown to un-
dergo further degradation both
in vitro (8) and in vivo (7,10),
generating a BNP form that
lacks the two N-terminal aa res-
idues (BNP3-32 or proBNP79-108).
Very recently, Brandt et al. (11)
demonstrated that this degra-
dation occurred by the action of
purified dipeptidyl peptidase IV
in vitro. This aminodipeptidase
preferentially cleaves dipeptides
from peptides with a proline or
lanine in the second N-terminal position. Importantly,
Figure 1 ProBNP Processing
ProBNP is a 108-amino acid (aa) precursor protein which is cleaved by the endopr
proBNP77-108) and the inert 76 aa N-terminal-proBNP peptide (proBNP1-76). Each fr
BNP  B-type natriuretic peptide.
Abbreviations
and Acronyms
aa  amino acid
ALVD  asymptomatic left
ventricular dysfunction
BNP  B-type natriuretic
peptide
BSA  body surface area
CV  cardiovascular
EF  ejection fraction
GFR  glomerular filtration
rate
HF  heart failure
MDC  minimal detectable
concentration
NT  N-terminal
ROC  receiver operating
characteristicroBNP also possesses a proline in the second position.
hus, it too may be susceptible to dipeptidyl peptidase IV
Figs. 2 and 3) and be processed to proBNP3-108, but this
as not been examined.
Recognizing the growing evidence for diverse circulating
roBNP products, our objectives were to determine whether 2
ikely alternate proBNP and BNP forms (BNP3-32 and
roBNP3-108) circulate in human plasma in the general pop-
lation. We also sought to determine if levels of these altered
orms differ according to age, gender, body size, renal function,
r the presence of CV disease, ALVD, or chronic HF within
he general population. Lastly, we sought to compare the
bility of these novel assays to identify persons with ALVD or
hronic HF with that of commercial assays, specifically the
iosite Triage BNP assay and the Roche NT-proBNP assay.
ethods
his study was approved by the Mayo Institutional Review
oard.
corin to form the bioactive 32 aa BNP peptide (referred to as BNP1-32 or as
t undergoes further N-terminal dipeptidase digestion, as might proBNP itself.otease
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March 20, 2007:1193–202 Alternate Circulating proBNP Productstudy setting, population sampling, subject recruitment,
nd characterization. The characteristics of the Olmsted
ounty, Minnesota, population, unique aspects of community-
ased research, and methods used to sample, recruit, and
haracterize the population have been previously described
12). Briefly, a total of 2,042 subjects were recruited from a
andom sample of the population 44 years. Each subject’s
edical record was reviewed by trained nurse chart abstrac-
ors using established criteria for hypertension, myocardial
nfarction, or HF (12). Clinical diagnoses of coronary artery
isease, valvular heart disease, cardiomyopathy, atrial fibril-
ation, transient ischemic attack or stroke, and diabetes
ellitus were also recorded.
oppler echocardiography. Echocardiographic methods
or the measurement of EF and diastolic function in this
tudy population have been extensively described (12).
iastolic function was categorized as normal, mild dysfunc-
ion (“impaired relaxation”), moderate dysfunction
“pseudonormal filling”), and severe dysfunction (“restrictive
lling”) (12). Of 2,042 subjects, 1,838 (90%) had EF
ssessment, determination of diastolic function, and ascer-
ainment of the presence or absence of CV disease, allowing
lassification into the subject groups.
ubject groups. Subjects were classified into 4 groups
Table 2): 1) normal control subjects with systolic blood
Figure 2 Commercial BNP or NT-proBNP Assays
Commercial BNP or NT-proBNP assays utilize dual antibody systems which recogni
NT-proBNP assay combines a capture antibody targeting proBNP aa 1-21 with a de
bines the monoclonal Scios 106.3 antibody, which binds somewhere in the proBN
proBNP aa 79-108 region. Other abbreviations as in Figure 1.ressure 140 mm Hg at the time of echocardiography, lody mass index 30 kg/m2, normal systolic function
EF 40%) and normal or only mildly abnormal diastolic
unction in the absence of CV disease (normal group);
) subjects with CV disease but normal systolic function
EF 40%) and normal or only mildly abnormal diastolic
unction (CV disease group); 3) subjects with ALVD,
efined as EF 40% and/or moderate to severe diastolic
ysfunction but no HF diagnosis (ALVD group); and
) subjects with chronic HF, defined as those diagnosed
ith HF before entry into the study (HF group).
ovel immunoassay development. Two potential alter-
ate circulating proBNP products were identified on the
asis of previous studies. Shimizu et al. (7) reported that
4% of spiked recombinant BNP1-32 underwent proteolytic
leavage of its N-terminal Ser-Pro aa residues when incu-
ated in whole blood, generating the dominant fragment
NP3-32. This form of N-terminal X-Pro trimming has
een observed with other signal peptides (13) and demon-
trated to occur in serum (14) and intracellular vesicles (15).
rimming by aminodipeptidases such as dipeptidyl pepti-
ase IV has been suggested to explain the observed proteo-
ytic cleavage of recombinant BNP1-32 in vitro, with similar
ccurrence in vivo (10). Aminodipeptidase cleavage could
ikewise occur at the N-terminal His-Pro motif of
roBNP1-108 were proBNP1-108 to circulate. Indeed, pre-
eparate segments of BNP1-32 or of NT-proBNP1-76, respectively. (Left) The Roche
n antibody recognizing proBNP aa 39-50. (Right) The Biosite Triage assay com-
2-90 region, with the Biosite polyclonal antibody, which binds somewhere in theze 2 s
tectio
P aa 8iminary experiments using a chip-based platform coated
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Alternate Circulating proBNP Products March 20, 2007:1193–202ith anti-BNP antibodies and mass analysis have demon-
trated the existence of both proBNP3-108 and BNP3-32 in
solated patient plasma samples (16). On the basis of these
ata, two novel immunoassays were developed by Biosite;
he Biosite proBNP3-108 assay and the Biosite BNP3-32
ssay (described hereafter and in Fig. 3). Proteolysis of
ynthetic BNP was subsequently confirmed at the Biosite
aboratory, where recombinant BNP1-32 (nesiritide) or ex-
ressed proBNP1-108 was spiked into ethylenediaminetet-
aacetic acid (EDTA) anti-coagulated plasma and analyzed
fter incubation using the BNP3-32 and proBNP3-108 assays.
he half-time for the formation of BNP3-32 from BNP1-32
as30 min, whereas that of proBNP3-108 from proBNP1-108
as approximately 2 h.
roBNP3-108 assay. A monoclonal antibody specific to the
-terminal end of proBNP3-108 was raised by immunizing
ice with a proBNP3-108 peptide segment synthesized from
he proBNP3-108 sequence. Antibody selection by phage
anning ensured specificity for the N-terminal end of
roBNP3-108. This antibody was paired with the Biosite
olyclonal antibody used in the Triage assay, which binds
omewhere in the proBNP79-108 region, to produce the
roBNP3-108 assay (Fig. 3, Table 1). To confirm specificity
f the assay for the N-terminus of proBNP3-108,
roBNP1-108 was cloned and expressed (mammalian cells).
he measured cross-reactivity with proBNP1-108 was
10%. proBNP3-108 was cloned and expressed (mammalian
ells) and used to calibrate and define the MDC of the
roBNP3-108 assay.
NP3-32 (proBNP79-108) assay. A monoclonal antibody
pecific to the N-terminal end of BNP3-32 was raised by
mmunizing mice with a BNP3-32 peptide segment synthesized
rom the BNP3-32 sequence. Antibody selection by phage
anning ensured specificity for the N-terminal end of
NP3-32. This antibody was paired with the Biosite poly-
lonal antibody used in the Triage assay to produce the
NP3-32 assay (Fig. 3, Table 1). To confirm specificity,
ross-reactivity tests with expressed proBNP1-108,
roBNP3-108 and BNP1-32 were performed. Cross-reactivity
as 10% in all cases. The Triage BNP test was shown to
xhibit 100% cross-reactivity with BNP3-32 by both spike
nd recovery experiments with expressed BNP3-32 and by
ack of a signal change during proteolysis of BNP1-32 to
NP3-32 in EDTA plasma. BNP3-32 was used to calibrate
he BNP3-32 assay and to define the MDC.
lasma collection and analysis. Blood was collected from
ach subject in the fasting state in EDTA-treated tubes and
laced on ice. After centrifugation at 2,500 rpm and 3°C,
he plasma was stored at 80°C. A 1-ml aliquot of frozen
lasma was shipped to Biosite Diagnostics (San Diego,
alifornia), where nonextracted samples were batch ana-
yzed using the proBNP3-108, BNP3-32 and Triage immu-
oassays. A second aliquot was analyzed at the Mayo Clinic
ore Laboratory (Rochester, Minnesota) using the Roche
T-proBNP assay as previously described (17). Assayperformance characteristics are summarized in Table 1 andT B B B R *B
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March 20, 2007:1193–202 Alternate Circulating proBNP Productsllustrated in Figures 2 and 3. Serum creatinine was mea-
ured in each subject at the Mayo Central Clinical Labora-
ory using the standard colorimetric Jaffe reaction. Glomer-
lar filtration rate (GFR) was estimated using the
odification of diet in renal disease equation.
Figure 3 Biosite ProBNP3-108 and BNP3-32 Assays
(Left) The proBNP3-108 assay combines an antibody specific for the N-terminus aa 3 o
BNP3-32 assay combines an antibody specific for the N-terminus aa 3 of BNP with 
Patient Characteristics
Table 2 Patient Characteristics
Normal
(n  613)
CV Di
(n  1
Age (range) (yrs) 57 (45–96) 63 (4
Male (%) 46 4
BSA (m2) 1.83 0.20 1.94
Creatinine (mg/dl) 1.02 0.15 1.07
GFR (ml/min/1.73 m2) 76.4 17.3 82.7
EF (%) 63 5 64
Diastolic dysfunction (%)
Normal 92 7
Mild 8 2
Moderate 0
Severe 0
Hypertension (%) 0 5
Coronary disease (%) 0 1
Obesity (%) 0 5
Diabetes (%) 0 1
Data are mean  SD except where indicated. *Chi-square or analysis
ALVD  asymptomatic left ventricular dysfunction; BSA  body surface a
filtration rate; HF  heart failure.tatistical methods. Based on the skewed distribution of
ssay results, natural log transformation was used in regres-
ion analyses to satisfy modeling assumptions. Comparisons
etween groups used ANOVA for continuous variables
with log transformation as appropriate) and chi-square
NP with the Biosite polyclonal antibody used in the Triage assay. (Right) The
osite polyclonal antibody used in the Triage assay. Abbreviations as in Figure 1.
ALVD
(n  130)
Chronic HF
(n  52) p Value*
70 (47–89) 73 (48–89) 0.01
47 64 0.1
1.86 0.23 1.90 0.26 0.01
1.09 0.21 1.25 0.45 0.01
66.7 34.7 63.9 35.7 0.01
59 11 47 14 0.01
0.01
2 4
4 37
89 37
6 22
60 81 0.01
29 85 0.01
29 40 0.01
9 25 0.01
nce p values as appropriate.f proB
the Bisease
,043)
5–94)
8
0.24
0.22
33.6
6
1
9
0
0
4
4
0
0
of varia
rea; CV  cardiovascular; EF  ejection fraction; GFR  glomerular
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Alternate Circulating proBNP Products March 20, 2007:1193–202nalysis for discrete variables. Unadjusted and adjusted
ssociations of assay results were evaluated using Spearman’s
orrelation coefficient and linear least-squares regression,
espectively. The ability of each assay to detect ALVD or
F was evaluated using receiver operating characteristic
ROC) curves. The area under each ROC curve was used to
est the null hypothesis of true area  0.5. Statistical
ignificance was judged at the 0.05 level.
esults
ubject groups. Subject group characteristics are shown in
able 2.
ssays results in persons without CV disease or ventric-
lar dysfunction (normal group). ProBNP3-108 levels were
bove the MDC in 68% of normal subjects. Levels of
roBNP3-108 increased with age (R  0.12, p  0.009),
ere higher in women than in men (20.52  28.88 pmol/l
s. 12.81  17.09 pmol/l, p  0.0001), and decreased with
ncreasing BSA (R0.13, p 0.005) or increasing GFR
R  0.20, p  0.001). Persons with detectable
roBNP3-108 were older (p  0.001), more frequently
emale (p  0.001), and had lower GFR (p  0.001) and
SA (p  0.014) than those with results below the MDC.
n multivariate linear regression modeling adjusting for age,
ender, creatinine, and BSA, the positive association be-
ween log proBNP3-108 and age, female gender, and creat-
nine remained significant (adjusted p  0.05 for all).
B-type natriuretic3-32 levels were above the MDC in only
2% of normal subjects. There was no association between
NP3-32 levels and age, BSA, or GFR (p 0.05 for all) and
orderline significant association with gender (p  0.038).
ersons with detectable BNP3-32 levels did not differ from
hose with levels below the MDC in regards to age, gender,
ody size, or renal function.
Figure 4 Percentage of Subjects With Detectable Assay Result
Bars represent the percentage of subjects in each group (see text) with measured
for between-group comparisons are given for each assay. ALVD  asymptomatic le
heart failure; MDC  minimal detectable concentration; NT  N-terminal.The Biosite Triage and Roche NT-proBNP results were
bove the MDC in 77% and 94%, respectively, of normal
ubjects. Both commercial assay results were positively
ssociated with age, female gender, worsening renal func-
ion, and smaller body size, whereas persons with detectable
esults were older, more likely female, and had lower GFR
nd BSA than persons with results below the MDC (data
ot shown).
ssay results in persons with CV disease, ALVD, or
hronic HF. The percentage of persons with assay results
bove the MDC increased across the four groups for the
roBNP3-108, Biosite Triage, and Roche NT-proBNP
ssays, but not the BNP3-32 assay (Fig. 4). Assay results
re summarized in Figure 5, where immunoreactivity in
mol/l was calculated for each assay using the molecular
eight of its specific calibrating peptide. proBNP3-108
ANOVA p  0.001), BNP3-32 (ANOVA p  0.013),
iosite Triage (ANOVA p  0.001), and Roche NT-
roBNP (ANOVA p  0.001) levels varied significantly
cross the groups. Adjusting for age, gender, creatinine,
nd BSA, proBNP3-108 levels were higher in ALVD than
V disease and higher in HF than ALVD. B-type
atriuretic peptide3-32 levels were higher in HF than
LVD. Both the Biosite Triage and the Roche NT-
roBNP assay results were increased in each group as
ompared with the previous one. Based on median molar
mmunoreactivity, the ratio of proBNP3-108, Biosite Triage
nd the Roche NT-proBNP was essentially 1:1:1 except in
hronic HF, where higher immunoreactivity was observed
or the Roche NT-proBNP assay.
Receiver operating characteristic analyses for detection of
LVD and HF are shown in Figure 6. Although both
roBNP3-108 and BNP3-32 demonstrated some diagnostic
tility, neither was superior to the Biosite Triage or Roche
T-proBNP assays for the diagnosis of ALVD or HF.
above the minimal detectable concentration of each assay. Chi-square p values
tricular dysfunction; BNP  B-type natriuretic peptide; CV  cardiovascular; HF s
levels
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March 20, 2007:1193–202 Alternate Circulating proBNP ProductsIn persons with normal systolic and normal or only
lightly abnormal diastolic function (normal and CV disease
roups combined), there was moderate correlation between
he proBNP3-108 and Biosite Triage results (R  0.32, p 
.001) as well as between proBNP3-108 and Roche NT-
roBNP results (R  0.34, p  0.001). The correlation
etween proBNP3-108 and Biosite Triage results (R  0.65,
 0.001) and between proBNP3-108 and Roche NT-
roBNP results (R  0.61, p  0.001) appeared stronger in
ersons with ventricular dysfunction with or without HF
ALVD and HF groups combined). The BNP3-32 assay
esults did not correlate with the Biosite Triage or the
oche NT-proBNP assay results in either of these
roups.
iscussion
his study, using both novel and commercially available
roBNP product assay systems, suggests that proBNP
rocessing is diverse, as proBNP3-108 was found to circulate
n subjects from the general population, even in those
ithout CV disease or ventricular dysfunction. Levels of
roBNP3-108 correlated with age, gender, body size, and
enal function and with the results of commercially available
roBNP product assays. proBNP3-108 levels were higher in
hose with ALVD or chronic HF, where they were more
trongly correlated with results from the Biosite Triage and
Figure 5 Assay Results by Subject Group
Boxplots showing median, interquartile range, minimum, and maximum observed i
p  0.05 for comparison of mean values between that group and the previous gro
Figure 4.oche NT-proBNP assays. B-type natriuretic peptide3-32 fas less frequently detected and, when present, was not
orrelated with age, body size, or renal function, although
evels of BNP3-32 were higher in subjects with chronic HF.
either the proBNP3-108 nor the BNP3-32 assay was supe-
ior to commercially available assays for the detection of
LVD or HF.
roBNP3-108. Previous studies using high-pressure liquid
hromatography have suggested that intact proBNP circu-
ates in HF (5–8). However, these studies involved very
mall numbers of patients with severe HF; used small,
elected groups of normal individuals as control subjects;
nd could not discriminate between proBNP1-108 and
roBNP3-108. Here selection bias was reduced by using a
opulation-based cohort. The current data further extend
revious high-pressure liquid chromatography studies by
emonstrating that the aminodipeptidase proteolyzed prod-
ct of proBNP1-108 (proBNP3-108) circulates, even in per-
ons without CV disease or ventricular dysfunction.
The current findings are also consistent with a previous
ttempt at the development of a proBNP1-108-specific assay
hat combined a monoclonal antibody targeting proBNP aa
5-80 with a polyclonal antibody directed against a site on
NP1-32 (proBNP77-108) (18). Our dual antibody system,
owever, spans the full polypeptide sequence of
roBNP3-108 more completely than the previous assay. This
hould avoid cross-reaction with other potential fragments
oreactivity in pmol/l by subject group (see text). For each assay, *represents
justing for age, gender, creatinine, and body surface area. Abbreviations as inmmun
up, adormed by endoprotease digestion along the N-terminal tail
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revious studies, one must conclude that proBNP1-108 is
eleased into the circulation even in normal human
ubjects in the general population. ProBNP1-108 then under-
oes processing to ProBNP3-108, ProBNP1-76 (NT-proBNP)
nd BNP1-32, the latter further degraded to BNP3-32 as
iscussed below. Further studies are clearly needed to
nderstand the biologic actions of these processed forms.
The association of proBNP3-108 with age, gender, body
ize, and renal function in the normal cohort of this
opulation-based study deserves attention. We and others
ave previously reported that commercially available assay
esults show similar associations. Alterations in BNP or
T-proBNP synthesis, degradation or clearance with age,
ender, body size, and renal function have been postulated
o explain the variation of commercial assay levels with these
ariables (17,19,20). However, as commercially available
ssays may cross-react with proBNP1-108 and proBNP3-108
9), altered proBNP processing with increases in proBNP or
ts aminodipeptidase proteolyzed fragment may also con-
ribute to the variability of commercial assays with age,
Figure 6 ROC Curves for Detection of ALVD and HF
(A) ROC curves for detection of ALVD using the different assays. (B) ROC curves f
of HF using the different assays. AUC  area under the curve; other abbreviationsender, renal function, and body size. pMore importantly, the markedly but variably increased
esults on commercial assays in persons with HF may be due in
art to altered proBNP processing with elevation of circulating
roBNP3-108 (and potentially intact proBNP1-108). A pre-
iminary report from Dries et al. (21) described an inverse
elationship between corin and BNP messenger ribonucleic
cid in cardiac tissue harvested from patients with end-stage
F, suggesting that the capacity to process proBNP may
ecrease as the signal for enhanced proBNP production
ncreases. The increased levels of proBNP3-108 in ALVD
nd HF, nearly equivalent relative molar concentrations
f proBNP3-108, Biosite Triage and Roche NT-proBNP
n ALVD, and enhanced correlation between proBNP3-108
nd the Biosite Triage and Roche NT-proBNP assay results
n persons with LV dysfunction are consistent with this
oncept. Further, the higher median molar immunoreac-
ivity observed with the Roche NT-proBNP assay relative
o the other assays in chronic HF may be due to more
omplete cross-reaction with all proBNP3-108, NT-
roBNP1-76 and other fragments, rather than to reduced
learance of the NT- proBNP1-76 fragment as previously
ection
Figure 4.or det
 as in ostulated.
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March 20, 2007:1193–202 Alternate Circulating proBNP ProductsNP3-32. In this population-based study, levels of BNP3-32
ere above the MDC in only a small percentage of normal
ubjects and in less than half of those with HF. Further,
espite the previously mentioned 100% cross-reactivity of
he Biosite Triage assay with BNP3-32 demonstrated during
ssay development, levels of BNP3-32 did not correlate with
he results of the Biosite Triage assay. These findings may
e interpreted in a number of ways. One could conclude that
ittle BNP1-32 is subject to aminopeptidase processing in
ivo or that BNP3-32 exists only transiently and is subse-
uently further digested. However, unlike ANP, both
NP1-32 and BNP3-32 were resistant to degradation by
urified neutral endopeptidases in vitro (11). Further, the in
itro data in this study suggest that BNP1-32 is rapidly and
tably digested to BNP3-32. Alternatively, one could also
onclude that the low levels of BNP3-32 reflect a low level of
roBNP cleavage by corin, a conclusion supported by the
ack of correlation between the Biosite Triage assay and the
NP3-32 assay, the observation that BNP3-108 is reliably
etected at significant levels, and the observed correlation
etween BNP3-108 and the Biosite Triage assay. These data
upport the emerging concept that commercial assays tar-
eting BNP1-32 are not specific for BNP1-32 and may be
ross-reacting with proBNP, its aminodipeptidase proteo-
yzed fragment, or other alternatively processed forms.
F as a natriuretic peptide-deficient state. Historically,
F was first postulated to be a natriuretic peptide-deficient
tate, as immunohistochemistry studies and bioactivity as-
ays indicated that atria from hamsters in HF were deficient
n atrial natriuretic peptide (22,23). However, development
f plasma natriuretic peptide assays subsequently indicated
ncreased circulating natriuretic peptide levels in HF (24).
et instead of increased natriuretic effect expected with
ncreased levels, overt HF patients display fluid and salt
etention. Mechanisms for end-organ resistance to elevated
atriuretic peptide levels have been invoked to explain this
pparent paradox (25,26). However, our data lend further
upport to the alternative and highly novel hypothesis that
bnormal proBNP processing, with reduced levels of bio-
ogically active natriuretic peptide forms, may contribute to
his paradox. Possible underlying mechanisms for altered
roBNP processing include inadequate corin gene expres-
ion (21), corin mutations (27), alternate proBNP process-
ng by furin (28), or differential degradation by neutral
ndopeptidase (29). Preliminary findings from an in vitro
tudy demonstrated that BNP3-32 activated the second
essenger guanosine 3=,5=-cyclic monophosphate (cGMP)
o a similar extent as BNP1-32 in cultured cardiac fibroblasts,
hereas proBNP1-108 had no bioactivity (30). Although this
n vitro study suggests that BNP3-32 is as active as BNP1-32,
recent in vivo study showed reduced bioactivity (hypoten-
ive, natriuretic, and cGMP generation effects) with
NP3-32 when equimolar doses of BNP3-32 and BNP1-32
ere infused (31). Interestingly, the reduced bioactivity was
ssociated with a similarly reduced increment in BNP
mmunoreactivity in response to the infusion, questioninghe stability of BNP3-32 in vivo. Further studies are needed
o better understand the role of alternate BNP processing as
ell as the bioactivity and degradation of alternately pro-
essed forms in HF.
tudy limitations. This study does not account for all
ossible altered forms of proBNP or BNP and cannot define
he extent to which commercial assays cross-react with these
lternate forms. Because of the use of expressed BNP3-108 to
alibrate the assay and the possible effect of glycosylation
hanges in native compared to expressed protein (32),
onclusions could not be made based on exact value assign-
ents (absolute concentration) of the Biosite proBNP3-108
ssay. As aminodipeptidase processing has been demon-
trated to occur in vitro, sample handling may contribute to
esults of the BNP3-32 assay. However, samples in this study
ere collected and stored in a highly consistent fashion.
onclusions
his study provides further evidence that proBNP process-
ng is diverse, even in individuals without CV disease or
entricular dysfunction. Further studies are needed to ascer-
ain the level to which commercial BNP assays cross-react
ith these and other alternate proBNP products and to
efine the biologic activity of circulating alternate proBNP
roducts. We speculate that commercial proBNP product
ssays, proven to be excellent biomarkers reflective of HF
resence and severity, may not be good indicators of
ndogenous natriuretic peptide bioactivity.
eprint requests and correspondence: Dr. Margaret M. Redfield,
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